13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001224962
Total reported value
$6.7B
$6.7B
108 檔
23.3%
As reported in its official Q1 2024 Form 13F filing, Perceptive Advisors LLC's tracked investment portfolio stood at $6.7B with 108 total positions.
During Q1 2024, Perceptive Advisors LLC's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
In terms of portfolio concentration, the top 5 core holdings (including CERE1EUR, AM6, IOVA) accounted for 23.3% of total reported equity market value during Q1 2024.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | CERE1EUR | Cerevel Therapeutics Holding | Stock-Other | 7.98% | — | -1.55% | |
| 2 | AM6 | Amicus Therapeutics Inc | Stock-Other | 5.78% | — | — | |
| 3 | IOVA | Iovance Biotherapeutics Inc | Stock-Other | 5.00% | — | +60.88% | |
| 4 | ACLXGBX | Arcellx Inc | Stock-Other | 4.79% | — | -13.45% | |
| 5 | NUVL | Nuvalent Inc-a | Stock-Other | 3.66% | -0.23% | -4.61% | |
| 6 | INBXUSD | Inhibrx Inc | Stock-Other | 2.60% | — | — | |
| 7 | ✓ | Fusion Pharmaceuticals Inc | Stock-Other | 2.55% | — | +148.07% | |
| 8 | RYTM | Rhythm Pharmaceuticals Inc | Stock-Other | 2.48% | +0.28% | +51.74% | |
| 9 | APGE | Apogee Therapeutics Inc | Stock-Other | 2.40% | +0.08% | +12.72% | |
| 10 | PCVX | Vaxcyte Inc | Stock-Other | 2.31% | — | +77.56% | |
| 11 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 2.30% | — | — | |
| 12 | MDT | Medtronic plc | Stock-Healthcare | 2.18% | — | +46.37% | |
| 13 | MDGL | Madrigal Pharmaceuticals Inc | Stock-Healthcare | 2.01% | — | +184.45% | |
| 14 | SWTXUSD | Springworks Therapeutics Inc | Stock-Other | 1.95% | — | +15.59% | |
| 15 | NBIX | Neurocrine Biosciences Inc | Stock-Healthcare | 1.94% | -0.17% | EXIT | |
| 16 | IMVT | Immunovant Inc | Stock-Other | 1.73% | +0.01% | +31.58% | |
| 17 | SYRE | Spyre Therapeutics Inc | Stock-Other | 1.70% | +2.03% | -1.92% | |
| 18 | BHVN | Biohaven Ltd. | Stock-Other | 1.65% | — | — | |
| 19 | SLDB | Solid Biosciences Inc | Stock-Other | 1.61% | +0.11% | +97.56% | |
| 20 | CATBUSD | Astria Therapeutics Inc | Stock-Other | 1.60% | — | +61.97% | |
| 21 | AXSM | Axsome Therapeutics Inc | Stock-Healthcare | 1.54% | -0.06% | +6.49% | |
| 22 | VKTX | Viking Therapeutics Inc | Stock-Healthcare | 1.43% | — | — | |
| 23 | EOLS | Evolus Inc | Stock-Other | 1.41% | +0.16% | +45.17% | |
| 24 | LYRAGBP | Lyra Therapeutics Inc | Stock-Other | 1.39% | — | — | |
| 25 | IRON | Disc Medicine Inc | Stock-Other | 1.35% | — | +21.19% | |
| 26 | CRGX | Cargo Therapeutics Inc | Stock-Other | 1.35% | — | +0.33% | |
| 27 | ITCIEUR | Intra-cellular Therapies Inc | Stock-Other | 1.28% | — | +877.18% | |
| 28 | NTRA | Natera Inc | Stock-Healthcare | 1.21% | +0.14% | NEW | |
| 29 | CRNX | Crinetics Pharmaceuticals In | Stock-Other | 1.21% | — | +17.58% | |
| 30 | MGTX | MeiraGTx Holdings plc | Stock-Other | 1.20% | +0.44% | — | |
| 31 | SRPT | Sarepta Therapeutics Inc | Stock-Healthcare | 1.19% | — | +16.33% | |
| 32 | VRDN | Viridian Therapeutics Inc | Stock-Other | 1.12% | -0.29% | +111.37% | |
| 33 | VRNA | Verona Pharma PLC - Adr | Stock-Other | 1.06% | — | -2.71% | |
| 34 | APLT | Applied Therapeutics Inc | Stock-Other | 1.01% | — | +85.69% | |
| 35 | CGON | Cg Oncology Inc | Stock-Other | 1.00% | — | — | |
| 36 | AORT | Artivion Inc | Stock-Other | 0.99% | -0.58% | +186.57% | |
| 37 | ARVN | Arvinas Inc | Stock-Other | 0.89% | — | +249.24% | |
| 38 | CELC | Celcuity Inc | Stock-Other | 0.89% | -1.95% | +59.47% | |
| 39 | PRAX | Praxis Precision Medicines I | Stock-Other | 0.88% | -2.59% | — | |
| 40 | RCKT | Rocket Pharmaceuticals Inc | Stock-Other | 0.85% | — | +5.49% | |
| 41 | ✓ | Immatics NV | Stock-Other | 0.84% | -0.42% | +31.24% | |
| 42 | TARS | Tarsus Pharmaceuticals Inc | Stock-Other | 0.82% | — | — | |
| 43 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 0.76% | — | -19.26% | |
| 44 | ADMA | Adma Biologics Inc | Stock-Healthcare | 0.74% | -0.07% | — | |
| 45 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 0.74% | -0.05% | +317.54% | |
| 46 | ✓ | Verrica Pharmaceuticals Inc | Stock-Other | 0.74% | — | — | |
| 47 | ISRG | Intuitive Surgical Inc | Stock-Healthcare | 0.71% | -0.46% | +85.09% | |
| 48 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 0.67% | — | -18.95% | |
| 49 | NAUT | Nautilus Biotechnology Inc | Stock-Other | 0.65% | -0.62% | — | |
| 50 | AKRO | Akero Therapeutics Inc | Stock-Other | 0.61% | — | +43.37% |
According to official SEC Form 13F filings, Perceptive Advisors LLC reported a total U.S. public equity portfolio value of $6.7B across 108 disclosed positions in Q1 2024.
During Q1 2024, Perceptive Advisors LLC's top holdings by market value included CERE1EUR (8.0%)、AM6 (5.8%)、IOVA (5.0%). The largest single position, CERE1EUR, represented 8.0% of total portfolio value.
In Q1 2024, Perceptive Advisors LLC made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.